Asterand Awarded Key Patents (0493E)
March 31 2011 - 9:33AM
UK Regulatory
TIDMATD
RNS Number : 0493E
Asterand PLC
31 March 2011
For Immediate Release 31 March 2011
ASTERAND PLC
Asterand Awarded Key Patents on the BioMAP Technology
Asterand plc (LSE: ATD), a leading provider of human
tissue-based services to pharmaceutical and biotechnology companies
engaged in drug discovery research, and its subsidiary BioSeek LLC
today announced that the United States Patent and Trademark Office
has issued U.S. Patent Nos. 7,908,089 entitled "Patient
classification" and 7,912,651 entitled "Function homology
screening." The patents cover key methods and applications of the
company's ground-breaking BioMAP(R) Systems technology.
Patent 7,908,089 relates to BioMAP and its use for the
classification of clinical patient tissue specimens according to
the physiological status of cells present in the sample. Key
embodiments of the invention include the ability to classify
patients by assaying their cells in vitro to determine response to
therapeutic agents and treatments or the status of activity within
pathways of interest. This information may be useful in patient
prognosis and diagnosis and can be used to develop surrogate
markers for disease states
Patent 7,912,651 covers key methods of cell selection, culture
conditions and screening of biologically active agents utilised by
the BioMAP Systems technology. Key features of the invention
include the identification of complex conditions for simultaneous
detection of a large number of cellular pathways and the rapid
screening and identification of compounds that cause cellular
responses. These methods are useful for the characterisation and
prioritisation of drug candidates and compounds based on their
impact on human biology. BioSeek scientists are the inventors on
both patents, which further strengthens the Company's intellectual
property around BioMAP(R) technology.
Martyn Coombs, Chief Executive Officer of Asterand
commented:
"Our BioMAP(R) technology represents a truly unique approach and
addresses a major unmet need in drug development for model systems
that reflect the complexity of human disease. These issued patents
represent a key advance as we continue building the intellectual
property portfolio around this platform."
BioMAP(R) Systems are primary cell-based models of human disease
biology, designed to replicate the intricate cell and pathway
interactions as they are observed in human pharmacology and
toxicology. Depending on their mechanism of action, drug compounds
induce specific patterns of changes in these systems (BioMAP(R)
profiles) that can be compared to a large number of reference
profiles in the BioMAP(R) Database. BioMAP(R) provides insight into
human pharmacological and toxicological properties of compounds,
including on- and off-target effects, dose responses, and the
discrimination of closely related compounds.
Contacts:
Asterand plc
Martyn Coombs, Chief Executive Officer Tel: + 44 (0) 1763 211
600 /
+ 1 (313) 263-0960
John Stchur, Chief Financial Officer As above
Buchanan Communications
Lisa Baderoon / Mark Court / Isabel Podda Tel: +44 (0) 20 7466
5000
Daniel Stewart & Company plc
Antony Legge Tel: +44 (0) 20 7776 6566
Martin Lampshire Tel: +44 (0) 20 7776 6550
About ASTERAND
Asterand plc is a leading supplier of high quality human tissue
and tissue-based services. Our comprehensive approach to human
tissue and research services offers pharmaceutical, biotech and
diagnostic companies the unique opportunity to have one company
meet all of their human biomaterial needs along the continuum of
drug discovery and development. Our mission is to accelerate target
discovery and compound validation and enable pharmaceutical and
biotechnology companies to take safer and more effective drugs into
the market.For more information about Asterand or BioSeek, go to
www.asterand.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCJBMITMBJJBTB
Bioseek (LSE:ATD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioseek (LSE:ATD)
Historical Stock Chart
From Jul 2023 to Jul 2024